Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights
Retrieved on:
Wednesday, August 4, 2021
This is an exciting time in our Companys history as we plan for a steady stream of milestones in the second half of 2021, commented Filippo Petti, Chief Executive Officer of Celyad Oncology.
Key Points:
- This is an exciting time in our Companys history as we plan for a steady stream of milestones in the second half of 2021, commented Filippo Petti, Chief Executive Officer of Celyad Oncology.
- Research & Development Day held on July 20, 2021, during which the management team provided:
Updates on the allogeneic CAR T clinical candidates CYAD-211 and CYAD-101. - Report additional data from the dose-escalation Phase 1 CYCLE-1 trial evaluating CYAD-02 in r/r AML and MDS by year-end 2021.
- Key financial figures for the first half of 2021, compared with the first half of 2020 and full year 2020, are summarized below: